Answers are grounded in this paper and cite their sources.
Preclinical study reveals that CXCL1/2 blockade enhances chemotherapy efficacy in glioblastoma models, highlighting a dual strategy against tumor survival.
T cell accumulation in vitro and in vivo. CXCL1/2 also promoted the paracrine factor S100A9 and further activated Erk1/2 and p70S60k, whereas blocking CXCL1/2 down-regulated these prosurvival factors. The combination of targeting CXCL1/2 and standard temozolomide chemotherapy improved upon the antitumor efficacy of chemotherapy alone, extending the overall survival time in GBM.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: